Genzyme Successfully Completes Phase 4 Study of Fabrazyme(r)

10-Sep-2004

Genzyme Corp. announced today that it has successfully completed its principal Phase 4 study of Fabrazyme(r) (agalsidase beta) and performed a preliminary analysis of the results. Completing this study was one of several requirements specified by the food and Drug Administration when it approved the product for the treatment of Fabry disease in April 2003. Fabry disease is a very rare and potentially fatal hereditary disorder that can lead to renal failure, heart disease and stroke.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances